{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:25:50Z","timestamp":1780975550895,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.oret.2022.01.019","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T20:52:57Z","timestamp":1643748777000},"page":"484-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes"],"prefix":"10.1016","volume":"6","author":[{"given":"Clement K.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maziar","family":"Lalezary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-4616","authenticated-orcid":false,"given":"Prema","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-1242","authenticated-orcid":false,"given":"Wesley Thomas","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-1353","authenticated-orcid":false,"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok S.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis K.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Lujan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-3310","authenticated-orcid":false,"given":"Glenn","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2022.01.019_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","article-title":"Prevalence of age-related maculopathy. The Beaver Dam Eye Study","volume":"99","author":"Klein","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.01.019_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","article-title":"Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study","volume":"114","author":"Klein","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.01.019_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/archopht.121.5.658","article-title":"Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study Cohort","volume":"121","author":"Wang","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib5","first-page":"2237","article-title":"Incidence and progression rates of age-related maculopathy: the Rotterdam Study","volume":"42","author":"Klaver","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2022.01.019_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/jamaophthalmol.2018.2019","article-title":"Association of genetic variants with response to anti\u2013vascular endothelial growth factor therapy in age-related macular degeneration","volume":"136","author":"Lor\u00e9s-Motta","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jamaophthalmol.2018.0032","article-title":"Understanding variation in response to anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"136","author":"Maguire","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients treated in the Marina and Anchor trials","volume":"149","author":"Barbazetto","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archopht.125.10.1323","article-title":"Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group","volume":"125","author":"Solomon","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib12","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.ophtha.2013.03.017","article-title":"Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"Maguire","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.01.019_bib13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamaophthalmol.2019.1947","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab","volume":"137","author":"Parikh","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000329473","article-title":"Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study","volume":"226","author":"Silva","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2022.01.019_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","article-title":"An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group","volume":"39","author":"Bird","year":"1995","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","article-title":"A\u00a0simplified severity scale for age-related macular degeneration: AREDS Report no. 18","volume":"123","author":"Ferris","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.01.019_bib18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","article-title":"The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17","volume":"123","author":"Davis","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib19","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1167\/iovs.13-11804","article-title":"Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2)","volume":"54","author":"Danis","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2022.01.019_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jamaophthalmol.2016.2383","article-title":"Evaluating the validity of the Age-Related Eye Disease Study grading scale for age-related macular degeneration: AREDS2 Report 10 Report 10","volume":"134","author":"Vitale","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2022.01.019_bib22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A\u00a0randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No 8","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib23","first-page":"2005","article-title":"Lutein\u00a0+ zeaxanthin and omega-3 fatty acids for age-related macular degeneration. Age-Related Eye Disease Study 2 (AREDS 2) randomized clinical trial","volume":"209","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2022.01.019_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archopht.1997.01100150743009","article-title":"Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/IAE.0b013e3180cc2612","article-title":"Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration","volume":"27","author":"Chan","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.01.019_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0002-9394(88)90011-6","article-title":"The pathogenesis of tears of the retinal pigment epithelium","volume":"105","author":"Chuang","year":"1988","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00417-002-0505-8","article-title":"Pigment epithelial detachment in the 368 elderly. Clinical differentiation, natural course and pathogenetic implications","volume":"240","author":"Pauleikhoff","year":"2002","journal-title":"Graefes. Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2022.01.019_bib28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/IAE.0b013e3182993f66","article-title":"Multimodal imaging of pigment epithelial detachment: a guide to evaluation","volume":"33","author":"Mrejen","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2022.01.019_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamaophthalmol.2021.0221","article-title":"Intravitreal Aflibercept injection vs sham as prophylaxis against conversion to exudative age-related macular degeneration in high-risk eyes: a randomized clinical trial","volume":"139","author":"Heier","year":"2021","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022000410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653022000410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:30:16Z","timestamp":1762853416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653022000410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2468653022000410"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2022.01.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2022.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}